IFNAR

The interferon-α/β receptor (IFNAR) is composed of two subunits, IFNAR1 and IFNAR2, encoding transmembrane polypeptides. Type-I IFNs, interferon α (IFN-α) and interferon β (IFN-β), act through a shared receptor complex, IFNAR. Binding of type-I IFN to IFNAR1 will robustly activate Janus activated kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Aberrant activation of the type-I IFN response results in a spectrum of disorders called interferonopathies.

Type-I IFN response occurs when IFN-α/β binds to their receptor complex, IFNAR. The ligand-receptor complex is phosphorylated, presumably by pre-associated Janus activated kinases (JAKs) namely tyrosine kinase 2 (TYK2) on IFNAR1 and JAK1 on IFNAR2. The phosphorylated receptors are docking sites for signal transducers and activators of transcription (STAT) factors that dimerise and translocate to the nucleus. STATs 1, 2, 3, 4, and 5 are activated by type-I IFNs in many cell types. Other kinases (e.g., mitogen-activated protein kinases) and transcription factors (e.g., nuclear factor-κB) can also be activated in response to type-I IFNs. Multiple pathways and IFN-regulated genes are activated by IFNs, many of which remain unknown.

IFNAR 相关产品（6）

货号	产品名	Cas	产品描述
PL01091	2',3'-cGAMP sodium		2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) 是一种哺乳动物细胞中的内源性 cGAMP。2',3'-cGAMP sodium 以高亲和力结合 STING，是干扰素-β (IFNβ) 的有效诱导物。2',3'-cGAMP sodium 是在哺乳动物细胞中为响应细胞质中的 DNA 而产生。
PL06342	Cridanimod	38609-97-1	Cridanimod 是一种有效的孕酮受体 (PR) 激活剂，通过诱导 IFNα 和 IFNβ 的表达可显着增加 PR 的表达。Cridanimod 是一种小分子免疫调节剂和干扰素诱导剂。
PL02929	IFN alpha-IFNAR-IN-1 hydrochloride	2070014-98-9	IFN alpha-IFNAR-IN-1 盐酸盐是一种非肽、低分子量的 IFN alpha 及其受体 IFNAR 相互作用抑制剂。IFN alpha-IFNAR-IN-1 盐酸盐抑制小鼠骨髓来源的 Flt3- l 分化的 pDC 培养物中，改良牛痘病毒 (MVA) 介导的 IFN-α 反应，IC50 为 2-8 μM。
PL02013	Interferon receptor inducer-1	2215120-36-6	Interferon receptor inducer-1 (compound 6) 是干扰素 (IFN) 受体的一个诱导剂。可用于研究干扰素诱导参与的紊乱性疾病。
PL06061	Sifalimumab	1006877-41-3	Sifalimumab (MEDI-545) 是一种 anti-IFNα 单克隆抗体，通过与多种干扰素-α 亚型结合来抑制异常的免疫活动。Sifalimumab 可用于系统性红斑狼疮 (SLE) 的研究。
PL02596	SM-276001	473930-22-2	SM-276001 是一种有效的选择性 TLR7 激动剂，可以诱导抗肿瘤免疫反应。SM-276001 是一种具有口服活性的干扰素 (IFN) 诱导剂。